EMA Provides an Outlook on the Product-Specific Bioequivalence Guidelines Expected in 2026
Recommendation
Thursday, 3 September 2026 9 .00 - 17.00 h
Establishment, Use and Maintenance of Analytical Reference Substances
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
EMA’s product-specific bioequivalence guidances describe, in a standardised format, how bioequivalence (BE) should be demonstrated.
On 19 May 2026, the EMA added the item “Product-specific guidelines that can be expected for 2026” to its website.
The following products are listed:
- Aripiprazole
- Cladribine
- Etonogestrel
- Fidaxomicin
- Ivacaftor
- Liraglutide
- Naproxen
- Niraparib
- Piribedil
- Raltegravir
- Rifaximin
- Semaglutide (tablets + SC solution)
- Tafamidis
- Tofacitinib
Further information is available on the EMA website.
Related GMP News
19.08.2026FDA Warning Letter: Averaging Data to Override OOS Findings
12.08.2026ECA's Analytical Control Group Publishes Detailed Report on OOS Survey
12.08.2026BP Publishes Key Insights on Limits in Chromatographic Tests
04.08.2026BioPhorum Publishes a Roadmap for QC Sample Test Execution
04.08.2026USP AISQ Virtual Workshop: ECA AQCG Board Members Contributed as Speakers
04.08.2026Several FDA Warning Letters and Untitled Letters on Asbestos Testing of Talc in OTC Drug Products